-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Sangamo Therapeutics, Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2015 to Q1 2025.
- Sangamo Therapeutics, Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $15K.
- Sangamo Therapeutics, Inc annual Deferred Income Tax Expense (Benefit) for 2024 was $0.000.
- Sangamo Therapeutics, Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$6.34M.
- Sangamo Therapeutics, Inc annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)